Brief: Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX

Akero Therapeutics

10/11/2023 14:02

Nov 10 (Reuters) - Akero Therapeutics Inc  AKRO.O :
    * AKERO THERAPEUTICS - ANALYSES FROM HARMONY, SYMMETRY
STUDIES
SHOW IMPROVEMENTS RELATED WITH EFX DON'T APPEAR ATTRIBUTABLE TO
CONCOMITANT USE OF GLP-1
    * AKERO THERAPEUTICS - BELIEVE LONGER PERIODS OF TREATMENT
WITH
EFX MAY RESULT IN HIGHER RATES OF FIBROSIS IMPROVEMENT,
INCLUDING CIRRHOSIS REVERSAL
    * AKERO THERAPEUTICS INC - ENCOURAGED THAT EFX APPEARS TO
PROVIDE
ADDITIONAL BENEFIT WHEN DOSED ON TOP OF GLP-1 THERAPY

Source text for Eikon:  ID:nGNX7ZQVmY 
Further company coverage:  AKRO.O 

 ((Reuters.Briefs@thomsonreuters.com;))